Camp, short for cyclic adenosine monophosphate, is the first discovered second messenger. It plays pivotal roles in cell signaling, regulating numerous physiological and pathological processes. Camp mainly exerts its functions through the protein kinase A (PKA) pathway and downstream effectors like cAMP-responsive element binding protein (CREB). It can also phosphorylate kinases such as Raf, GSK3, and FAK. Camp is involved in various cellular activities including cell growth, migration, invasion, and metabolism [1].

Aberrant Camp-PKA signaling is associated with different types of human tumors. Depending on the tumor types and context, Camp signaling can have both tumor-suppressive and tumor-promoting roles. Small-molecule agents that inhibit adenylate cyclase and PKA, as well as Camp-elevating agents like forskolin, have shown potential in cancer therapy [1,2].

In conclusion, Camp is a crucial second messenger regulating a wide range of cellular functions. Its dysregulation is implicated in cancer, and understanding its role in tumorigenesis through functional studies, potentially including gene knockout (KO) or conditional knockout (CKO) mouse models in future research, may provide new therapeutic strategies for cancer treatment.